Area of research
Oncology · Surgery
Research interest
Research interests include Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes, and Colorectal Cancer Treatments and Studies.
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> fusions/rearrangements.
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i>-paclitaxel plus gemcitabine (<i>nab</i>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring <i>FGFR2</i> gene rearrangements.